Expected milestone payment on achieving certain regulatory and commercial milestones.

No definition available.

Name:	dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones
Namespace Prefix:	dsgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Expected royalty payments upon first commercial product sale.

+ References

No definition available.

+ Details

Name:	dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale
Namespace Prefix:	dsgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Milestone payment

+ References

No definition available.

+ Details

Name:	dsgn_MilestonePayment
Namespace Prefix:	dsgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Notice period description.

+ References

No definition available.

+ Details

Name:	dsgn_NoticePeriodDescription
Namespace Prefix:	dsgn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Notice period for termination of agreement.

+ References

No definition available.

+ Details

Name:	dsgn_NoticePeriodForTerminationOfAgreement
Namespace Prefix:	dsgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential milestone payments.

+ References

No definition available.

+ Details

Name:	dsgn_PotentialMilestonePayments
Namespace Prefix:	dsgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Schedule of license agreement.

+ References

No definition available.

+ Details

Name:	dsgn_ScheduleOfLicenseAgreementLineItems
Namespace Prefix:	dsgn_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Uncured period of agreement in event of breach of agreement notice.

+ References

No definition available.

+ Details

Name:	dsgn_UncuredPeriodOfAgreementInEventOfBreachOfAgreementNotice
Namespace Prefix:	dsgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront payment upon execution of agreement.

+ References

No definition available.

+ Details

Name:	dsgn_UpfrontPaymentUponExecutionOfAgreement
Namespace Prefix:	dsgn_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Written Notice period to terminated agreement.

+ References

No definition available.

+ Details

Name:	dsgn_WrittenNoticePeriodToTerminatedAgreement
Namespace Prefix:	dsgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Written notice period to terminated license agreement in event of breach of agreement.

+ References

No definition available.

+ Details

Name:	dsgn_WrittenNoticePeriodToTerminatedLicenseAgreementInEventOfBreachOfAgreement
Namespace Prefix:	dsgn_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 985
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-14

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479532/912-730-25-1

+ Details

Name:	us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Details

Name:	us-gaap_StatementOfIncomeLocationBalanceAxis=us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dsgn_InvestigationNewDrugMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License Agreements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025	Dec. 31, 2025	Dec. 31, 2022
Schedule Of License Agreement [Line Items]
Research and development	$ 16,388,000	$ 15,738,000	$ 30,767,000	$ 31,115,000
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense
Schedule Of License Agreement [Line Items]
Upfront payment upon execution of agreement			$ 300,000
License Agreement
Schedule Of License Agreement [Line Items]
Milestone payment						$ 100,000
Written notice period to terminated agreement			60 days
Written notice period to terminated license agreement in event of breach of contract			30 days
Uncured period of agreement in event of breach of agreement notice			60 days
Written notice period for termination of agreement			90 days
Termination period Description			WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries.
Research and development					$ 100,000
License Agreement \| Maximum
Schedule Of License Agreement [Line Items]
Potential milestone payments			$ 800,000
License Agreement \| Investigation New Drug (IND) \| Maximum
Schedule Of License Agreement [Line Items]
Expected milestone payment on achieving certain regulatory and commercial milestones	17,500,000		17,500,000
License Agreement \| Investigation New Drug (IND) \| Minimum
Schedule Of License Agreement [Line Items]
Expected royalty payments upon first commercial product sale	$ 100,000		$ 100,000